Alexander Mundinger：

Alexander Mundinger：

2023.11.27
Cost-Effectiveness of Breast Cancer Screening Editor's Note: The 2023 China Congress of Integrative Oncology (2023 CCHIO) will be held in Tianjin from November 16th to 19th, 2023. Dr. Alexander Mundinger,…

Prof. Zhong-Qiu Lin: Creating a Protective Umbrella for the Cancer Prevention and Treatment of Chinese Women

2023.11.22
Protecting the health of Chinese women and providing a robust defense against gynecological cancer requires the integration of more resources and efforts in the field of gynecological cancer prevention and treatment. On the eve of the "2023 Chinese Congress on Holistic Integrative Oncology (2023 CCHIO)," Oncology Frontier interviewed Prof. Zhong-Qiu Lin, Chairman of the Cervical Cancer Professional Committee of the China Anti-Cancer Association and Sun Yat-sen Memorial Hospital, to discuss the current status of gynecological cancer prevention and treatment in China, recent advances in maintenance therapy for advanced-stage cases, and the developmental vision of the Cervical Cancer Professional Committee of the China Anti-Cancer Association.
ESMO Hot Topic | Professor Han Liang : Phase III MATTERHORN Study on the Verge of Success, Significant Improvement in pCR with Neoadjuvant Durvalumab for Gastric Cancer

ESMO Hot Topic | Professor Han Liang : Phase III MATTERHORN Study on the Verge of Success, Significant Improvement in pCR with Neoadjuvant Durvalumab for Gastric Cancer

2023.11.17
The 2023 ESMO Annual Meeting took place from October 20th to 24th in Madrid, Spain. As a highly authoritative annual event in the field of oncology, it unveils cutting-edge advancements in cancer research each year. In the gastric cancer domain this year, the global Phase III MATTERHORN study on the anti-PD-L1 monoclonal antibody durvalumab was presented as a Late-breaking Abstract (LBA) with mid-term analysis results (Abstract No: LBA73). The interim analysis revealed a clinically and statistically significant increase in the pathologic complete response (pCR) rate with the neoadjuvant treatment regimen of durvalumab in combination with FLOT. The MATTERHORN study holds promise as the first positive neoadjuvant Phase III immunotherapy regimen for gastric cancer. "Oncology Frontier" is pleased to invite Professor Han Liang from Tianjin Medical University Cancer Institute to provide an in-depth interpretation of this study.
ESMO Exclusive Interview | Professor Changsong Qi: CAR-T Therapy IM96 Shows Significant Antitumor Activity in Advanced Colorectal Cancer with GCC Expression

ESMO Exclusive Interview | Professor Changsong Qi: CAR-T Therapy IM96 Shows Significant Antitumor Activity in Advanced Colorectal Cancer with GCC Expression

2023.11.17
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place in Madrid, Spain, from October 20th to 24th. The Oncology Frontier team delved into the frontline, capturing international advancements and witnessing the strides made by China in the global oncology arena. Professor Changsong Qi from Peking University Cancer Hospital delivered a crucial oral presentation (Abstract No: 1018O) at this conference. In an exclusive interview with Oncology Frontier, Professor Qi shared insights from his reported research and thoughts on colorectal cancer studies presented at this year's ESMO. This article compiles relevant content for readers.
ESMO 2023丨Professor Zhimin Shao: monarcE Study 5-Year Follow-Up Data Revealed, Sustained Benefit for Patients

ESMO 2023丨Professor Zhimin Shao: monarcE Study 5-Year Follow-Up Data Revealed, Sustained Benefit for Patients

2023.11.17
The monarchE study is a randomized, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of abemaciclib combined with endocrine therapy versus endocrine therapy alone in HR+, HER2-high-risk early-stage breast cancer patients. Since the disclosure of relevant data in March 2020, the study results have been updated multiple times, establishing the standard position of abemaciclib combined with endocrine therapy. At the 2023 ESMO Congress, Professor Nadia Harbeck, the lead investigator of the monarchE study from the University of Munich, Germany, announced the milestone data results of the 5-year follow-up. In this regard, Professor Zhimin Shao, the lead investigator of the monarchE study, director of the Institute of Oncology and Institute of Breast Cancer Research at Fudan University, and director of the Department of Surgery at Fudan University Affiliated Tumor Hospital, provided an introduction and interpretation of the monarchE study results.